Quratis operates at the intersection of biotechnology innovation and contract development and manufacturing. Guided by a mission to promote human well-being through improved quality of life, its vision is to become an innovative company where everyone aspires to work. Its core values—quality, unity, respect, advancement, technology, integrity and safety—shape its approach to R&D, manufacturing and partnerships.

The company is engaged in developing next-generation vaccines (including tuberculosis and COVID-19 candidates), immune adjuvant platforms, cell therapy technologies and peptide nucleic acid (PNA) therapeutics. In parallel, it offers robust CDMO and CMO services, supplying end-to-end support from raw material and process development through to finished biologics manufacturing.

Quratis operates a purpose-built, GMP-compliant biomanufacturing facility located in Osong, Chungcheongbuk-do. Completed in August 2020 and spanning nearly 20,000 m², this site supports clinical and commercial production of biologics, compliant with cGMP, EU-GMP and KGMP standards.

Key Products & Services

Vaccine Candidates

QTP101: A tuberculosis vaccine incorporating ID93 antigen and the GLA-SE adjuvant.

QTP104: A next-generation self-replicating mRNA (repRNA) COVID-19 vaccine.

Adjuvant Platform

GLA-SE: A TLR-4 agonist adjuvant that enhances immune responses, reducing required antigen dosage and facilitating broader vaccine applicability.

CPP Platform

A proprietary cell/bacterial penetrating peptide drug-delivery system, applicable to antibiotics, antivirals and anticancer agents.

Peptide Nucleic Acid (PNA)

A synthetic DNA analogue with high specificity and stability, being developed as an antimicrobial agent targeting multidrug-resistant bacteria, including MDR-TB and Staphylococcus aureus.

CDMO & CMO Services

Full-service capabilities in biopharmaceutical development and manufacturing:

cGMP Biologics Production: From clinical trial to commercial scale, including microbial fermentation, sterile liquid and freeze-dried injectables.

Process and Formulation Development: Raw material processing, formulation design, process optimisation.

Analytical Method Development & Validation: Identity, potency, purity, stability testing, validation of systems and processes.

Scale-Up and Technical Transfer: Support across 50 L to 500 L fermentation scale and beyond.

Quality Assurance & Compliance: Adherence to cGMP, EU-GMP, KGMP, ICH guidelines with experienced QA teams

With robust R&D pipelines, including vaccine, adjuvant, cell therapy and PNA platforms, alongside a comprehensive CDMO infrastructure in Osong, Quratis stands as a versatile partner for biopharmaceutical development. Rooted in its commitment to quality and public health impact, the company continues to drive innovations across therapeutic modalities and manufacturing — advancing global access to essential biologics.